Following vaccination with melanoma peptides in a phase II trial of patients with metastatic melanoma, IFN-γ production by CD8+ T cells after ex vivo stimulation with the vaccinating melanoma peptides (measured by ELISPOT), but not the frequency or phenotype of antigen-specific T cells, correlated with clinical responses to the vaccine [27]. This evidence concerns the gene IFNG and melanoma.